COMPARISON OF BLADDER CANCER CELLS APOPTOSIS INDUCED BY METFORMIN, CISPLATIN, AND COMBINATION OF METFORMIN-CISPLATIN: IN VITRO STUDY

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

PDF
Published 2020-01-22
Arifai Lumbangaol Lukman Hakim Doddy M Soebadi Tarmono Djojodimedjo

Abstract

Objective: To evaluate the effect of metformin, cisplatin, and their combination on apoptosis of bladder cancer cells. Material & Methods: Urothelial cell lines 5637 were cultured until 80% confluence. Cells were exposed to metformin and cisplatin at certain doses for 24 and 48 hours. Cytotoxicity test was carried out by calculating the viability of bladder cancer cells using the MTT assay until IC50 of each drug was obtained. IC50 Metformin and Cisplatin obtained from the cytotoxicity test were used to induce apoptosis in bladder cancer cells using TUNEL assay. Additional combination doses of Metformin and cisplatin used to induce apoptosis were ¼ IC50 (metformin + cisplatin), ½ IC50 (metformin + cisplatin), and IC50 (metformin + cisplatin). Results: IC50 of metformin was 15 uM while cisplatin was 18 uM with a 48-hour exposure. There was a difference in the mean value of the apoptosis index in all treatment groups compared to control except for the group exposed to IC50 metformin and ¼ IC50 (metformin + cisplatin). Conclusion: Metformin administration solely is not able to increase bladder cancer cell apoptosis. Conversely, the administration of Cisplatin can significantly increase bladder cancer cell apoptosis. The combination of Metformin and Cisplatin can significantly increase bladder cancer cell apoptosis. The rate of apoptosis in line with an increase dose of the combination of these two drugs.


##plugins.themes.bootstrap3.article.details##

Keywords

Metformin, Cisplatin, Cytotoxicity, Apoptosis

References

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians. 2015; 65: 5-29.

Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27: 289-93.

Burger M. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013; 63: 234-41.

Stemberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. European Urology. 2013; 63: 58-66.

Serretta V, Morgia G, Altieri V, et al. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. British Journal of Urology International. 2010; 106: 212-217.

Bellmunt J. New therapeutic challenges in advanced bladder cancer. Semin Oncol. 2012; 39: 598.

Von der Maase H. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602.

Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011; 144: 646-674.

Evans JM, Donelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. British Medical Journal. 2005; 330: 1304-1305.

Ruiter R, Visser LE, Van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study. Diabetes Care. 2012; 35: 119-124.

Currie CJ, Poole CD, Jenkins-Jones S, et al. Mortality after incident cancer in people with and without type 2 diabetes: Impact of metformin on survival. Diabetes Care. 2012; 35: 299-304.

Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenograft involving multiple cancer cell types. Cancer Research. 2011; 71: 3196-3201.

Dalva-Aydemir S, Bajpai R, Martinez M, et al. Targetting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clinical Cancer Research. 2015; 21: 1161-1171.

Zhang T, Guo P, Zhang Y, et al. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells invitro and in vivo. Int J Mol Sci. 2013; 14: 24603-18.

Wang D, Wu X. In vitro and in vivo targetting of bladder carcinoma with metformin in combination with cisplatin. Oncol. Letters. 2015; 10: 975-981.

Juffs HG, Moore MJ, Tannock IF. The role of systematic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol. 2002; 3: 738-747.

Gupta S, Mahipal A. Role of systematic chemotherapy in urothelial urinary bladder cancer. Cancer Kontrol. 2013; 20: 200-210.

Herr HW, Dotan Z, Donat SM, et al. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007; 177: 437-443.

Peng Mei, Su Qiongli, Zeng Qing, et al. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. www.impactjournals.com. Oncotarget. 2016; 7(8): 9102-17.

Liu Qiuli, Yuan Wenqiang, Tong Dali, et al. Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. www.impactjournals.com. Oncotarget. 2016; 7(9): 28235-46.

Kordes S, Pollak MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomized, placebo-kontrolled phase 2 trial. Lancet Oncology. 2015; 16: 839-847.

Section
Articles
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University